MRIMath's AI-Powered Glioblastoma Tool Receives FDA Clearance

Key Insights

• MRIMath LLC's _i_ 2Contour, an AI-powered tool for glioblastoma mapping and measurement, has received FDA clearance, allowing its marketing to potential customers.
• The tool, co-developed by Rowan University and the University of Alabama at Birmingham, aims to improve efficiency and accuracy in tumor contouring, potentially reducing healthcare costs.
• _i_ 2Contour uses AI trained on MRI images to delineate tumor boundaries, assess previous scans, and predict tumor growth, enabling earlier detection and response to tumor development.

MRIMath LLC, a medical technology company co-founded by Rowan University and the University of Alabama at Birmingham, has received FDA clearance for its AI-powered tool, MRIMath i 2Contour, designed for mapping and measuring glioblastoma brain tumors. This clearance allows MRIMath to market the tool to healthcare providers, potentially improving patient outcomes and reducing healthcare costs.

How i 2Contour Works

i 2Contour is a cloud-based cyber tool that utilizes artificial intelligence to enhance the efficiency and accuracy of glioblastoma tumor mapping. Trained on a vast dataset of MRI images, the tool delineates tumor boundaries with pixel-level accuracy. It also assesses previous radiological scans to calculate tumor volume and predict growth trends using statistical methods. According to MRIMath, the device can save physicians hours per imaging study and significantly reduce bottlenecks in contouring, accelerating patient care.

Clinical Significance

Glioblastoma is the most common and deadly primary brain tumor in adults. The ability to accurately and quickly assess tumor characteristics, such as location, volume, and shape, is critical for effective treatment planning. Nidhal C. Bouaynaya, Ph.D., professor at Rowan University and co-founder of MRIMath, noted the challenges in anticipating tumor evolution, stating, "It’s incredibly challenging to anticipate tumor characteristics, such as location, volume and shape, as it evolves. AI is the best system for this level of complexity, as it can analyze vast amounts of data to accurately predict tumor characteristics."

Development and Support

MRIMath, LLC, received support from the Rowan Innovation Venture Fund, the National Institutes of Health Small Business Innovation Research (SBIR) program (Phases I and II), the National Science Foundation’s Innovation Corps, the New Jersey Commission on Science and Technology and the Innovate Alabama award. This support has been crucial in developing and validating the technology. The company reports that universities and hospital systems have already expressed interest in the product.